Skip to main content

Durvalumab Side Effects

Medically reviewed by Drugs.com. Last updated on Apr 22, 2023.

Applies to durvalumab: intravenous solution.

Serious side effects of Durvalumab

Along with its needed effects, durvalumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking durvalumab:

More common

Less common

Rare

Other side effects of Durvalumab

Some side effects of durvalumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to durvalumab: intravenous solution.

Endocrine

Common (1% to 10%): Immune-mediated endocrinopathies (e.g., hypothyroidism, hyperthyroidism, adrenal insufficiency, type 1 diabetes mellitus, hypophysitis/hypopituitarism)[Ref]

Dermatologic

Very common (10% or more): Rash (dermatitis, dermatitis acneiform, dermatitis psoriasiform, psoriasis, rash maculopapular, rash pruritic, rash papular, rash pustular, skin toxicity, eczema, erythema, erythema multiforme, rash erythematous, acne, lichen planus) (11%)[Ref]

Cardiovascular

Uncommon (0.1% to 1%): Immune-related myocarditis[Ref]

Hematologic

Very common (10% or more): Lymphopenia (11%)

Common (1% to 10%): Anemia[Ref]

Genitourinary

Very common (10% or more): Urinary tract infection (e.g., cystitis, candiduria, urosepsis) (15%)[Ref]

Gastrointestinal

Very common (10% or more): Constipation (21%), nausea (16%), abdominal pain (upper, lower, flank) (14%), diarrhea/colitis (13%)

Common (1% to 10%): Dehydration

Frequency not reported: Immune-mediated colitis[Ref]

Hepatic

Common (1% to 10%): Liver injury, immune-mediated hepatitis

Uncommon (0.1% to 1%): Increased ASO, increased ALT, hyperbilirubinemia

Frequency not reported: Immune-mediated hepatitis[Ref]

Metabolic

Very common (10% or more): Decreased appetite/hypophagia (19%), hyponatremia (12%)

Common (1% to 10%): Deterioration of general physical health, increased alkaline phosphatase, hypermagnesemia, hypercalcemia, hyperglycemia, neutropenia, hyperkalemia, hypoalbuminemia[Ref]

Local

Common (1% to 10%): Infusion-related reactions[Ref]

Immunologic

Common (1% to 10%): Infections (e.g., sepsis, necrotizing fasciitis, osteomyelitis)[Ref]

Ocular

Uncommon (0.1% to 1%): Uveitis and keratitis[Ref]

Musculoskeletal

Very common (10% or more): Musculoskeletal pain (e.g., back pain, musculoskeletal chest pain, musculoskeletal pain and discomfort, myalgia, neck pain) (24%)[Ref]

Nervous system

Common (1% to 10%): Pyrexia/tumor associated fever

Uncommon (0.1% to 1%): Immune-related aseptic meningitis[Ref]

Other

Very common (10% or more): Fatigue (e.g., asthenia, lethargy, malaise) (39%), peripheral edema (e.g., edema, localized edema, edema peripheral, lymphedema, peripheral swelling, scrotal edema, scrotal swelling) (15%), pyrexia/tumor associated fever (14%)

Common (1% to 10%): Embryofetal toxicity[Ref]

Renal

Common (1% to 10%): Acute kidney injury, increased creatinine[Ref]

Respiratory

Very common (10% or more): Dyspnea/exertional dyspnea (24%), cough/productive cough (10%)

Uncommon (0.1% to 1%): Immune-mediated pneumonitis[Ref]

Frequently asked questions

References

1. Product Information. Imfinzi (durvalumab). Astra-Zeneca Pharmaceuticals. 2017.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.